Gene Therapy Making a Comeback?

I worked for a gene therapy startup a number of years ago.  It was a very exciting concept then as now.  Gene therapy experienced a series of setbacks that nearly extinguished interest in the field in the late ’90s and early 2000’s.

I have recently come across a couple of examples of success of gene therapy projects.  Both are ex-vivo corrections of Mendelian gene disorders and both provide hints that the promise of gene therapy may some day be realized.

The first from Cartier and colleagues (Science 326: 818, 2009) described the correction of X-linked adrenoleukodystrophy in two boys using autologous hematopoietic cells carrying a functional ABCD1 gene introduced with a lentivirus vector.  The gene therapy appears to have succeeded out to 2 years.

The second report was recently published in Nature from Cavazzana-Calvo et al. (Nature 467:318, 2010).  The report describes correction of beta-thalassemia by autologous transplantation of gene-corrected hematopoietic cells.   In this case, an 10-year old patient has been able to forego transfusions for two years post-treatment.

I’m glad that our optimism of 15 years ago was not unfounded.  We should look for additional successes from gene therapy in the next few years.

This entry was posted in Gene Therapy. Bookmark the permalink.